ArticleEuropean journal of nuclear medicine and molecular imaging2026
FUO-PETMamba: a pet maximum-intensity-projection-based artificial intelligence framework for aetiological classification of fever of unknown origin with multicentre validation.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFever of unknown origin (FUO) remains diagnostically challenging because of heterogeneous causes, non-specific clinical manifestations, and overlapping imaging findings. We developed and validated FUO-PETMamba, a PET maximum-intensity-projection (MIP)-based artificial intelligence framework for AI-assisted aetiological classification of FUO.
methodsThis retrospective multicentre study included 681 patients with FUO who underwent baseline [18 F]FDG PET/CT, comprising one development cohort (n = 355) and two independent external validation cohorts (n = 195 and n = 131). FUO-PETMamba is a weakly supervised framework analysing PET MIP images generated from PET data. Model performance was assessed by discrimination, calibration, decision curve analysis (DCA). Attention-based visual explanations were generated using attention mechanisms and gradient-based activation mapping. A reader study assessed the potential assistive effect of model-predicted probabilities on physicians with different PET/CT experience.
resultsIn the development cohort, FUO-PETMamba achieved AUCs of 0.838 for malignancy, 0.851 for infection, 0.914 for autoimmune disease, and 0.788 for miscellaneous causes. Corresponding AUCs were 0.809, 0.815, 0.805, and 0.849 in external validation cohort 1, and 0.808, 0.772, 0.701, and 0.927 in external validation cohort 2, respectively. Calibration and decision curve analysis suggested potential clinical benefit for the major aetiological categories, although performance varied across cohorts and classes. The miscellaneous category should be interpreted cautiously because of limited case numbers and low positive predictive value and F1 scores. In the reader study, AI assistance improved diagnostic accuracy for junior and intermediate physicians, whereas changes in senior-physician performance were variable. Post hoc attention-based visualisations highlighted clinically plausible hypermetabolic patterns and served as qualitative explanatory aids.
conclusionsFUO-PETMamba provides a PET MIP-based AI-assisted diagnostic support framework for aetiological classification of FUO across multicentre cohorts and may help reduce experience-dependent diagnostic variability after prospective validation.
Indexed as
Identifiers
42435203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.